Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Serono/Pfizer Rebif Will Reach 30% Share By 2006, Serono Says

Executive Summary

Serono is increasing its market share projection for the multiple sclerosis agent Rebif by at least five percentage points in light of its co-promotion agreement with Pfizer
Advertisement

Related Content

Serono Rebif: 80% Of Rxs Are Switches, Efficacy Is Main Marketing Message
Serono Rebif: 80% Of Rxs Are Switches, Efficacy Is Main Marketing Message
Serono/Pfizer Rebif Co-Promotion Deal Will Use Neurontin Sales Force
Serono Rebif 25% Market Share Expected By 2006; Monthly Price Is $1,156
Serono Rebif 25% Market Share Expected By 2006; Monthly Price Is $1,156
Serono Rebif Approval Is First Orphan Drug Challenge Based On Efficacy
Advertisement
UsernamePublicRestriction

Register

PS040243

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel